Navigation Links
S*BIO's Oral JAK2 Inhibitor SB1518 Demonstrates Therapeutic Potential for the Treatment of Myeloproliferative and Other Hematological Disorders
Date:12/10/2007

57

SB939: A potent and orally-active HDAC inhibitor for the treatment of hematological malignancies

SB939, a novel histone deacetylase HDAC inhibitor with improved metabolic, pharmacokinetic and pharmacological properties compared to other HDAC inhibitors, is currently in Phase I clinical trials, and has demonstrated potential for the treatment of various types of hematological malignancies.

Poster No. 747

SB1317, a potent and orally-active FLT3-CDK inhibitor with high anti-tumor efficacy in models of hematological malignancies

SB1317, a novel potent inhibitor of FLT3 kinase and CDKs 1, 2 and 9, demonstrated therapeutic potential for the treatment of hematological malignancies. FLT3 is the most common mutated gene in acute myeloid leukemia

(AML), and CDK1, 2, and 9 are well-established anti-cancer targets due to their direct role in cell cycle control.

About S*BIO Pte Ltd

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, has entered the clinic in 2Q 2007. It recently announced that a second compound, SB1518, would enter the clinic in 1H 2008 and that a third compound, SB1317, is in pre-clinical development.

In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong linkages with a network of medical oncologists in Asia Pacific and its investors include Bio*One Capital, Novartis Bioventures and other international funds. More information about S*BIO can be found at http://www.sbio.com.

S*BIO Pte Ltd:

Stephen Keith Rhind, Ph.D.

Senior Vice President, Cor
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients
2. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
3. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
4. SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor
5. Silencing small but mighty cancer inhibitors
6. Investigational Agent Targeting Metabotropic Glutamate 2/3 Receptors Demonstrates Antipsychotic Activity in Humans, Study in Nature Medicine Finds
7. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
8. Highmarks Hospital Pay-for-Performance Program Demonstrates Impressive Results
9. Facet Solutions AFRS(TM) Implant Demonstrates Positive Clinical Results After One Year Follow Up
10. LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon
11. ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... (PRWEB) September 17, 2014 StartX ... revealed 12 companies raising rounds of funding at its ... few hundred investors and media, was the first such ... located next to the university. The presentations were delivered ... adjacent to StartX-QB3 Labs, a 2,000 square foot life ...
(Date:9/17/2014)... Cadiz Laser Spa offers the latest, most ... throughout Central Texas. The newest addition to their ... Using the revolutionary Rejuvapen micro-needling device Cadiz Laser ... a wide variety of skin issues. , The ... Spa is currently offering a special package through ...
(Date:9/17/2014)... (HealthDay News) -- Present-day Europeans are the descendants ... according to a new study. Previous ... and early European farmers. But, a new genetic ... also the descendants of Ancient North Eurasians. Nearly ... third ancestral group, researchers from Harvard Medical School ...
(Date:9/17/2014)... Steven Reinberg HealthDay Reporter ... a key factor to explain why antibiotic-resistant bacteria can thrive ... called plasmids appear to be the culprit. They can easily ... some carry a gene that makes bacteria drug-resistant, a new ... an antibiotic-resistant gene to a class of antibiotic called carbapenems," ...
(Date:9/17/2014)... might be able to reduce the need for invasive ... autoimmune disease lupus. , In a new study, researchers ... from nephritis kidney inflammation to interstitial fibrosis, ... A kidney biopsy is the only existing way to ... extent. , The model could also be used to ...
Breaking Medicine News(10 mins):Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 4Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 5Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 6Health News:Revolutionary Collagen Induction Therapy is Now Available at Cadiz Laser Spa 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 3Health News:Researchers Discover How Bacteria Resist Antibiotics in Hospitals 2Health News:Researchers Discover How Bacteria Resist Antibiotics in Hospitals 3Health News:Math model designed to replace invasive kidney biopsy for lupus patients 2
... Corporation today announced it has requisitioned a special meeting ... return of capital to NUCRYST shareholders of approximately US$15 ... review alternatives to maximize the value of its 74.5 ... Corporations Act, NUCRYST,s Board of Directors has 20 days ...
... N.J., Dec. 1 ETHICON, Inc., a Johnson & ... of its Professional Wound Care business to One Equity Partners. ... , , Under the terms ... Wound Care product portfolio, which contains such advanced wound care ...
... Dec. 1 Democratic National Committee Chairman Howard Dean today ... 20th Anniversary: , , (Logo: ... "It,s been 20 years since the first World AIDS Day, ... be done to tackle this epidemic with both a national ...
... MassMutual Retirement Services Division has added two new ... has more than tripled in 2008 compared to last ... Dan Darby joined MassMutual on December 1 as nonprofit ... M. Palmer Whitney, national managing director, nonprofit market, for ...
... failure, study says , , MONDAY, Dec. 1 (HealthDay News) ... that cause idiosyncratic drug-induced liver injury (DILI), researchers say. ... cases of acute liver failure in the United States ... acute liver failure. , DILI is caused by a ...
... (PTSD) affects as many as one in five of all ... or terrorism. It has emotionally paralyzed survivors of 9/11 and ... accepted treatment that can lower the chance of developing the ... medical means of preventing PTSD may be just around the ...
Cached Medicine News:Health News:The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders 2Health News:ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners 2Health News:ETHICON Completes Divestiture of Professional Wound Care Business to One Equity Partners 3Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 2Health News:MassMutual Retirement Services Adds Two to Nonprofit Sales Team 3Health News:Antibiotics Largest Cause of Drug-Induced Liver Damage 2Health News:Easing the stress of trauma 2
(Date:9/17/2014)... , Sept. 17, 2014 Bronstein, Gewirtz & ... purchasers of the securities of PDL BioPharma, Inc. ("PDL ... -News).  Such investors are advised to contact Peretz ... Kimelman at info@bgandg.com or 212-697-6484. ... certain of its executives violated federal securities laws. ...
(Date:9/17/2014)... 2014 , Glenmark,s ... positive data in a Phase 2a proof of concept ... Glenmark Pharmaceuticals today announced that its ... antagonist, GRC 17536 has shown positive data in a ... concept study conducted on 138 patients in ...
(Date:9/17/2014)... 17, 2014   MedeAnalytics today unveils ... brings complete visibility to a provider,s "mid-cycle" to ... reimbursement landscape. Powered by the industry,s leading big ... critical point between patient access and the business ... will improve revenue capture, minimize audit risk and ...
Breaking Medicine Technology:Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 2Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 3MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3
... Oct. 31, 2011 Covance Inc. (NYSE: ... ranked first, by a wide margin, in an independent ... trials. The majority (54 percent) of the study participants ... central laboratory, with investigators citing Covance three times more ...
... InterMune, Inc. (NASDAQ: ITMN ) today ... Shire plc, has been appointed to InterMune,s Board of ... on meeting the needs of the specialist physician. ... a leading global biopharmaceutical company with expertise in the ...
Cached Medicine Technology:Covance Central Laboratory Services Ranks #1 in Global Investigator Satisfaction Survey 2Covance Central Laboratory Services Ranks #1 in Global Investigator Satisfaction Survey 3InterMune Appoints Angus C. Russell to Board of Directors 2InterMune Appoints Angus C. Russell to Board of Directors 3
EPS 3501 : 3500 V, 150 mA, 100 W maximum. Constant voltage, constant current, or constant power modes. Stores and recalls three protocols. Excellent for manual DNA sequencing and IEF applications....
... power supply, with temperature probe, 100-120 and 220-240 ... 500 mA, and 400 W. The temperature probe ... and 90 degrees C during electrophoresis. Built-in infrared ... and instructions are provided. Dimensions are 27.5 x ...
... SPECIFICATIONS Form: Granular, free flowing powder EEO(-m r ): ... (3%): less than or equal to 31C Remelt ... Gel Strength (3%): greater than or equal to 500 ... equal to 1000 gm/cm 2 Moisture: less than ...
... chloride (Cl) ≤ 500 mg/kg sulfate (SO 4 ) ... Cd ≤ 5 mg/kg Co ≤ 5 mg/kg Cr ... 10 mg/kg K ≤ 50 mg/kg Mg ≤ 50 ... Ni ≤ 5 mg/kg Pb ≤ 5 mg/kg Zn ...
Medicine Products: